TY  - JOUR
A1  - Wolfahrt, Sonja
A1  - Herman, Sandra
A1  - Scholz, Claus-Jürgen
A1  - Sauer, Georg
A1  - Deissler, Helmut
T1  - Identification of alternative transcripts of rat CD9 expressed by tumorigenic neural cell lines and in normal tissues
JF  - Genetics and Molecular Biology
N2  - CD9 is the best-studied member of the tetraspanin family of transmembrane proteins. It is involved in various fundamental cellular processes and its altered expression is a characteristic of malignant cells of different origins. Despite numerous investigations confirming its fundamental role, the heterogeneity of CD9 or other tetraspanin proteins was considered only to be caused by posttranslational modification, rather than alternative splicing. Here we describe the first identification of CD9 transcript variants expressed by cell lines derived from fetal rat brain cells. Variant mRNA-B lacks a potential translation initiation codon in the alternative exon 1 and seems to be characteristic of the tumorigenic BT cell lines. In contrast, variant mRNA-C can be translated from a functional initiation codon located in its extended exon 2, and substantial amounts of this form detected in various tissues suggest a contribution to CD9 functions. From the alternative sequence of variant C, a different membrane topology ( 5 transmembrane domains) and a deviating spectrum of functions can be expected.
KW  - tetraspanin
KW  - CD9
KW  - antigen
KW  - cancer
KW  - noncoding RNAs
KW  - nervous system
KW  - poor prognosis
KW  - tetraspanin protein
KW  - transcript
KW  - splice variant
KW  - membrane topology
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-131801
VL  - 36
IS  - 2
ER  - 
TY  - JOUR
A1  - Kneitz, Burkhard
A1  - Kalogirou, Charis
A1  - Spahn, Martin
A1  - Krebs, Markus
A1  - Joniau, Steven
A1  - Lerut, Evelyne
A1  - Burger, Maximilian
A1  - Scholz, Claus-Jürgen
A1  - Kneitz, Susanne
A1  - Riedmiller, Hubertus
T1  - MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer
JF  - International Journal of Molecular Sciences
N2  - The treatment of high-risk prostate cancer (HRPCa) is a tremendous challenge for uro-oncologists. The identification of predictive moleculobiological markers allowing risk assessment of lymph node metastasis and systemic progression is essential in establishing effective treatment. In the current study, we investigate the prognostic potential of miR-205 in HRPCa study and validation cohorts, setting defined clinical endpoints for both. We demonstrate miR-205 to be significantly down-regulated in over 70% of the HRPCa samples analysed and that reconstitution of miR-205 causes inhibition of proliferation and invasiveness in prostate cancer (PCa) cell lines. Additionally, miR-205 is increasingly down-regulated in lymph node metastases compared to the primary tumour indicating that miR-205 plays a role in migration of PCa cells from the original location into extraprostatic tissue. Nevertheless, down-regulation of miR-205 in primary PCa was not correlated to the synchronous presence of metastasis and failed to predict the outcome for HRPCa patients. Moreover, we found a tendency for miR-205 up-regulation to correlate with an adverse outcome of PCa patients suggesting a pivotal role of miR-205 in tumourigenesis. Overall, we showed that miR-205 is involved in the development and metastasis of PCa, but failed to work as a useful clinical biomarker in HRPCa. These findings might have implications for the use of miR-205 as a prognostic or therapeutic target in HRPCa.
KW  - high-risk prostate cancer
KW  - microRNA
KW  - miR-205
KW  - prognosis
KW  - biomarker
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-97321
ER  -